You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Grail plans to raise a total of more than $1 billion before the end of the first quarter.
The Palo Alto-based firm plans to use the money to further validate its non-invasive, early cancer detection technology.
Elizabeth Mansfield, who spearheaded regulations at the agency for precision medicine and next-generation sequencing, will lead regulatory affairs at Illumina-backed Grail.
Illumina plans to speed up the process of making Grail an independent company and will no longer have representation on its board of directors.
The company is planning to work with up to 40 sites, with an initial goal of sequencing circulating cell-free DNA from 10,000 people.
Representatives from industry, academia, the FDA, and insurance companies gathered for a joint FDA- and American Association for Cancer Research-sponsored workshop.
In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.
National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.
Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.
In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.